Literature DB >> 21623461

The origins, specificity, and potential biological relevance of human anti-IgG hinge autoantibodies.

Randall J Brezski1, David M Knight, Robert E Jordan.   

Abstract

Human anti-IgG hinge (HAH) autoantibodies constitute a class of immunoglobulins that recognize cryptic epitopes in the hinge region of antibodies exposed after proteolytic cleavage, but do not bind to the intact IgG counterpart. Detailed molecular characterizations of HAH autoantibodies suggest that they are, in some cases, distinct from natural autoantibodies that arise independent of antigenic challenge. Multiple studies have attempted to define the specificity of HAH autoantibodies, which were originally detected as binding to fragments possessing C-terminal amino acid residues exposed in either the upper or lower hinge regions of IgGs. Numerous investigators have provided information on the isotype profiles of the HAH autoantibodies, as well as correlations among protease cleavage patterns and HAH autoantibody reactivity. Several biological functions have been attributed to HAH autoantibodies, ranging from house-cleaning functions to an immunosuppressive role to restoring function to cleaved IgGs. In this review, we discuss both the historic and current literature regarding HAH autoantibodies in terms of their origins, specificity, and proposed biological relevance.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21623461      PMCID: PMC5720009          DOI: 10.1100/tsw.2011.107

Source DB:  PubMed          Journal:  ScientificWorldJournal        ISSN: 1537-744X


  10 in total

1.  A monoclonal antibody against hinge-cleaved IgG restores effector function to proteolytically-inactivated IgGs in vitro and in vivo.

Authors:  Randall J Brezski; Michelle Kinder; Katharine D Grugan; Keri L Soring; Jill Carton; Allison R Greenplate; Theodore Petley; Dorie Capaldi; Kerry Brosnan; Eva Emmell; Sharon Watson; Robert E Jordan
Journal:  MAbs       Date:  2014-10-30       Impact factor: 5.857

2.  The in vitro resistance of IgG2 to proteolytic attack concurs with a comparative paucity of autoantibodies against peptide analogs of the IgG2 hinge.

Authors:  Randall J Brezski; Allison Oberholtzer; Brandy Strake; Robert E Jordan
Journal:  MAbs       Date:  2011-11-01       Impact factor: 5.857

3.  Recommendations for the Assessment and Management of Pre-existing Drug-Reactive Antibodies During Biotherapeutic Development.

Authors:  Li Xue; Adrienne Clements-Egan; Lakshmi Amaravadi; Mary Birchler; Boris Gorovits; Meina Liang; Heather Myler; Shobha Purushothama; Marta Starcevic Manning; Crystal Sung
Journal:  AAPS J       Date:  2017-11-06       Impact factor: 4.009

4.  Cleavage of IgG1 in gingival crevicular fluid is associated with the presence of Porphyromonas gingivalis.

Authors:  A Guentsch; C Hirsch; W Pfister; B Vincents; M Abrahamson; A Sroka; J Potempa; S Eick
Journal:  J Periodontal Res       Date:  2012-11-01       Impact factor: 4.419

5.  Molecular characterization of human anti-hinge antibodies derived from single-cell cloning of normal human B cells.

Authors:  Tao Huang; Mary Mathieu; Sophia Lee; Xinhua Wang; Yee Seir Kee; Jack J Bevers; Claudio Ciferri; Alberto Estavez; Manda Wong; Nancy Y Chiang; Gerald Nakamura; Randall J Brezski
Journal:  J Biol Chem       Date:  2017-11-30       Impact factor: 5.157

Review 6.  Pre-existing Antibody: Biotherapeutic Modality-Based Review.

Authors:  Boris Gorovits; Adrienne Clements-Egan; Mary Birchler; Meina Liang; Heather Myler; Kun Peng; Shobha Purushothama; Manoj Rajadhyaksha; Laura Salazar-Fontana; Crystal Sung; Li Xue
Journal:  AAPS J       Date:  2016-01-28       Impact factor: 4.009

7.  A single proteolytic cleavage within the lower hinge of trastuzumab reduces immune effector function and in vivo efficacy.

Authors:  Xuejun Fan; Randall J Brezski; Ming Fa; Hui Deng; Allison Oberholtzer; Anneliese Gonzalez; William P Dubinsky; William R Strohl; Robert E Jordan; Ningyan Zhang; Zhiqiang An
Journal:  Breast Cancer Res       Date:  2012-08-08       Impact factor: 6.466

Review 8.  Cross-reactive and pre-existing antibodies to therapeutic antibodies--Effects on treatment and immunogenicity.

Authors:  Karin A van Schie; Gerrit-Jan Wolbink; Theo Rispens
Journal:  MAbs       Date:  2015       Impact factor: 5.857

9.  Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies.

Authors:  Stephen Norris; Steven Ramael; Ippei Ikushima; Wouter Haazen; Akiko Harada; Viktoria Moschetti; Susumu Imazu; Paul A Reilly; Benjamin Lang; Joachim Stangier; Stephan Glund
Journal:  Br J Clin Pharmacol       Date:  2017-04-06       Impact factor: 4.335

10.  IgG anti-hinge antibodies against IgG4 F(ab')2 fragments generated using pepsin are useful diagnostic markers for rheumatoid arthritis: implications of the possible roles of metalloproteinases and IgG subclasses in generating immunogenic hinge epitopes.

Authors:  Toshiyuki Ota; Shun-Ichiro Ota; Ayumi Uchino; Shuji Nagano
Journal:  Arthritis Res Ther       Date:  2020-06-26       Impact factor: 5.156

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.